MiniMed Group, Inc.

424B4 priced

Price $20.00 · 28,000,000 shares · Gross proceeds $560,000,000

MiniMed Group, Inc. is conducting an initial public offering (IPO) of 28,000,000 shares of common stock at $20.00 per share, raising $560 million. Medtronic will retain 90.03% ownership post-offering, maintaining MiniMed as a 'controlled company' under Nasdaq rules. The offering includes an underwriter option to purchase additional shares, with proceeds intended for capital structure adjustments and separation-related transactions. The company will transition from Medtronic through a series of agreements, including asset transfers, tax arrangements, and employee matters.

EFFECT effective

MiniMed Group, Inc. filed a Notice of Effectiveness for its S-1 registration statement, effective March 5, 2026, confirming the availability of its common stock for trading on Nasdaq. The filing incorporates by reference the prospectus from the initial S-1 registration dated December 19, 2025, and subsequent amendments.

8-A12B effective

MiniMed Group, Inc. filed Form 8-A12B to register its common stock for listing on Nasdaq, referencing its prior S-1/A registration statement. The filing confirms the company’s intent to list 28 million shares at an estimated price range of $25-$28, with Medtronic retaining majority ownership. The registration incorporates details from the S-1/A, including the separation from Medtronic and underwriting arrangements.

CERT inactive

The current filing for MiniMed Group, Inc. is a CERT form dated 2026-03-05, following a previous EFFECT filing. The text appears corrupted or non-readable, making detailed analysis challenging. The previous filing was a Notice of Effectiveness for an S-1 registration, indicating the company's IPO process was approved.

S-1/A amended

Price $26.50 · Range $25.00 to $28.00 · 28,000,000 shares

MiniMed Group, Inc. is conducting an initial public offering (IPO) of 28,000,000 shares of common stock, with an estimated price range of $25.00 to $28.00 per share. The offering aims to separate the company from its parent, Medtronic, through a series of agreements, including the transfer of the Diabetes Operating Unit. Medtronic will retain 90.03% of voting shares post-offering, making MiniMed a 'controlled company' under Nasdaq rules. A subsequent divestment of Medtronic's remaining stake is planned, contingent on regulatory and market conditions.

S-1/A amended

Range $25.00 to $28.00 · 28,000,000 shares · Gross proceeds $742,000,000

MiniMed Group, Inc. is conducting an initial public offering (IPO) of 28,000,000 shares of common stock, with an estimated price range of $25.00 to $28.00 per share. The offering follows a separation from its parent company, Medtronic, which will retain 90.03% of voting power post-offering, making MiniMed a 'controlled company' under Nasdaq rules. The IPO includes detailed terms for the separation, tax matters, employee agreements, and a potential future divestment of Medtronic's remaining stake. Underwriters include Goldman Sachs, BofA Securities, and others.

S-1/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, following a separation from its parent company, Medtronic. The offering involves the transfer of Medtronic's Diabetes Operating Unit to MiniMed through a series of agreements, including a Separation Agreement, Tax Matters Agreement, and Employee Matters Agreement. Upon completion, Medtronic will retain a significant ownership stake, but plans to divest its remaining interest via a tax-free distribution, potentially a spin-off or split-off. The company intends to list on Nasdaq under the symbol 'MMED'.

S-1 filed

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, with the goal of separating from its parent company, Medtronic. The offering involves transferring the Diabetes Operating Unit's assets and liabilities to MiniMed, with Medtronic retaining a significant ownership stake. The company plans to list on Nasdaq under the symbol 'MMED'. The IPO follows a confidential DRS/A filing and includes detailed agreements related to the separation, tax matters, employee transitions, and potential future divestment of Medtronic's remaining shares.

DRS/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, with an estimated price range and planned listing on a stock exchange. The offering follows a separation from its parent company, Medtronic, involving the transfer of the Diabetes Operating Unit. Post-IPO, Medtronic will retain a majority stake, and a subsequent tax-free distribution to Medtronic shareholders is anticipated, though subject to conditions.

DRS/A amended

MiniMed Group, Inc. is conducting an initial public offering (IPO) of its common stock, following a planned separation from its parent company, Medtronic. The offering will be accompanied by a Distribution of Medtronic's remaining equity interest in the company. The filing outlines the Separation Agreement, tax matters, employee arrangements, and other transitional agreements with Medtronic, along with underwriting details and risk factors.

DRS filed

MDT Sub Holdings, Inc. (MiniMed Group, Inc.) is conducting its initial public offering (IPO) of common stock, separating from its parent company Medtronic. The offering involves transferring Medtronic's Diabetes Operating Unit to MDT Sub Holdings through a series of agreements, including a Separation Agreement, Tax Matters Agreement, and others. Medtronic will retain a majority stake post-offering, and a tax-free distribution to Medtronic shareholders is contemplated. The IPO aims to list shares on [exchange] under the ticker [symbol], with an estimated price range of $[value] to $[value].